Characterisation of macular neovascularisation subtypes in age-related macular degeneration to optimise treatment outcomes.
Characterisation of macular neovascularisation subtypes in age-related macular degeneration to optimise treatment outcomes.
复制标题
DOI：
10.1038/s41433-022-02231-y
复制
发表时间：
2023-06
期刊：
影响因子：
3.9
通讯作者：
Staurenghi, Giovanni
中科院分区：
文献类型：
--
作者：
Mathis, Thibaud;Holz, Frank G.;Sivaprasad, Sobha;Yoon, Young Hee;Eter, Nicole;Chen, Lee-Jen;Koh, Adrian;de Souza, Eduardo Cunha;Staurenghi, Giovanni
本文就新生血管性年龄相关性黄斑变性（nAMD）不同亚型的共同特征及临床表现进行综述。我们还就如何根据新生血管的亚型定制治疗以优化患者结局提出了建议。作者是Vision Academy的选定成员，根据黄斑新生血管形成（MNV）亚型，使用在PubMed数据库中进行的文献检索的证据（截止日期：2019年3月），讨论了nAMD的治疗结局。这篇综述文章总结了Vision Academy关于MNV亚型特征如何优化nAMD治疗结局的建议。多模态成像的出现促进了MNV亚型的鉴定。荧光素血管造影，吲哚菁绿色血管造影和光谱域光学相干断层扫描共同帮助改善和扩展MNV亚型的确定结果。到目前为止，文献中已经描述了三种亚型，并且通过成像鉴定具有特定特征。1型MNV与更好的长期结局相关，但通常需要更强烈的抗血管内皮生长因子剂量。2型MNV通常对治疗反应迅速，但更容易发生纤维化瘢痕，这可能与较差的结果有关。与其他亚型相比，3型MNV倾向于对抗血管内皮生长因子治疗高度敏感，但可能与更高的外视网膜萎缩发生率相关。准确评估MNV亚型可提供预后信息，并有助于优化nAMD患者的管理。
The aim of this review is to identify the common characteristics and prognoses of different subtypes of neovascular age-related macular degeneration (nAMD). We also propose recommendations on how to tailor treatments to the subtype of neovessels to optimise patient outcomes. The authors, selected members of the Vision Academy, met to discuss treatment outcomes in nAMD according to macular neovascularisation (MNV) subtypes, using evidence from a literature search conducted on the PubMed database (cut-off date: March 2019). This review article summarises the recommendations of the Vision Academy on how the characterisation of MNV subtypes can optimise treatment outcomes in nAMD. The identification of MNV subtypes has been facilitated by the advent of multimodal imaging. Findings from fluorescein angiography, indocyanine green angiography and spectral-domain optical coherence tomography collectively help refine and standardise the determination of the MNV subtype. To date, three subtypes have been described in the literature and have specific characteristics, as identified by imaging. Type 1 MNV is associated with better long-term outcomes but usually requires more intense anti-vascular endothelial growth factor dosing. Type 2 MNV typically responds quickly to treatment but is more prone to the development of fibrotic scars, which may be associated with poorer outcomes. Type 3 MNV tends to be highly sensitive to anti-vascular endothelial growth factor treatment but may be associated with a higher incidence of outer retinal atrophy, compared with other subtypes. Accurately assessing the MNV subtype provides information on prognosis and helps to optimise the management of patients with nAMD.
登录
查看更多内容
影响因子：
13.7
作者：
Daniel E;Pan W;Ying GS;Kim BJ;Grunwald JE;Ferris FL 3rd;Jaffe GJ;Toth CA;Martin DF;Fine SL;Maguire MG;Comparison of Age-related Macular Degeneration Treatments Trials
通讯作者：
Comparison of Age-related Macular Degeneration Treatments Trials
影响因子：
0.9
作者：
Kim JB;Nirwan RS;Kuriyan AE
通讯作者：
Kuriyan AE
影响因子：
4.2
作者：
Grossniklaus, HE;Gass, JDM
通讯作者：
Gass, JDM
DOI：
10.1097/iae.0000000000001279
发表时间：
2017-02-01
影响因子：
3.3
作者：
Dolz-Marco, Rosa;Phasukkijwatana, Nopasak;Freund, K. Bailey
通讯作者：
Freund, K. Bailey
影响因子：
4.1
作者：
Invernizzi, Alessandro;Teo, Kelvin;Gillies, Mark C.
通讯作者：
Gillies, Mark C.